Active Biotech AB (publ) (STO:ACTI)

Market Cap	149.07M -44.4%
Revenue (ttm)	n/a
Net Income	-34.72M
EPS	-2.15
Shares Out	26.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,789
Open	5.70
Previous Close	5.63
Day's Range	5.64 - 5.77
52-Week Range	3.70 - 25.35
Beta	1.36
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACTI

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error